Relay Therapeutics Inc.

2.48
0.01 (0.40%)
At close: Apr 02, 2025, 3:59 PM
2.39
-3.56%
After-hours: Apr 02, 2025, 07:55 PM EDT

Relay Therapeutics Statistics

Share Statistics

Relay Therapeutics has 169.52M shares outstanding. The number of shares has increased by 27.71% in one year.

Shares Outstanding 169.52M
Shares Change (YoY) 27.71%
Shares Change (QoQ) 1.28%
Owned by Institutions (%) 99.99%
Shares Floating 127.7M
Failed to Deliver (FTD) Shares 80.22K
FTD / Avg. Volume 3.37%

Short Selling Information

The latest short interest is 15.21M, so 9.09% of the outstanding shares have been sold short.

Short Interest 15.21M
Short % of Shares Out 9.09%
Short % of Float 12.28%
Short Ratio (days to cover) 5.71

Valuation Ratios

The PE ratio is -1.74 and the forward PE ratio is -1.81. Relay Therapeutics's PEG ratio is 0.11.

PE Ratio -1.74
Forward PE -1.81
PS Ratio 58.82
Forward PS 1.5
PB Ratio 0.76
P/FCF Ratio -2.34
PEG Ratio 0.11
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Relay Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 15.95, with a Debt / Equity ratio of 0.06.

Current Ratio 15.95
Quick Ratio 15.95
Debt / Equity 0.06
Debt / EBITDA -0.13
Debt / FCF -0.19
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $38.34K
Profits Per Employee $-1.29M
Employee Count 261
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -65.27% in the last 52 weeks. The beta is 1.65, so Relay Therapeutics's price volatility has been higher than the market average.

Beta 1.65
52-Week Price Change -65.27%
50-Day Moving Average 3.73
200-Day Moving Average 5.67
Relative Strength Index (RSI) 30.51
Average Volume (20 Days) 2.38M

Income Statement

In the last 12 months, Relay Therapeutics had revenue of 10.01M and earned -337.71M in profits. Earnings per share was -2.36.

Revenue 10.01M
Gross Profit 10.01M
Operating Income -372.47M
Net Income -337.71M
EBITDA -380.21M
EBIT -385.67M
Earnings Per Share (EPS) -2.36
Full Income Statement

Balance Sheet

The company has 124.29M in cash and 48.5M in debt, giving a net cash position of 75.78M.

Cash & Cash Equivalents 124.29M
Total Debt 48.5M
Net Cash 75.78M
Retained Earnings -1.74B
Total Assets 871.3M
Working Capital 758.48M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -249.11M and capital expenditures -2.02M, giving a free cash flow of -251.13M.

Operating Cash Flow -249.11M
Capital Expenditures -2.02M
Free Cash Flow -251.13M
FCF Per Share -1.76
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -3722.07% and -3374.72%.

Gross Margin 100%
Operating Margin -3722.07%
Pretax Margin -3374.72%
Profit Margin -3374.72%
EBITDA Margin -3799.44%
EBIT Margin -3722.07%
FCF Margin -2509.49%

Dividends & Yields

RLAY does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for RLAY is $18, which is 625.8% higher than the current price. The consensus rating is "Buy".

Price Target $18
Price Target Difference 625.8%
Analyst Consensus Buy
Analyst Count 10
Stock Forecasts

Scores

Altman Z-Score -0.35
Piotroski F-Score 1